Abstarct: This study examines and evaluates the quality risks present in the pharmaceutical supply chain. To achieve this, the Failure Modes and Effects Analysis (FMEA) approach is utilized for identifying and prioritizing existing risks. The case study of this research is Farabi Company. To gather the necessary information, including risks, potential failure modes, and required data for the FMEA form, the opinions of seven experts in the pharmaceutical supply chain field were used. Considering the nature of the research, it is classified as applied in terms of purpose and employs an interview-baxsed methodology. The results indicate that the risks of "entry of fake drugs," "inappropriate packaging," "delays in delivery," "printing incorrect information," "defects in control systems," and "failure to properly execute the inspection program" received the highest risk scores and had the greatest impact on reducing drug quality. Additionally, the findings from the analysis after implementing corrective actions show a significant improvement in risk scores. Accordingly, the new risk scores are all below 210, which is deemed acceptable for management. Finally, the study provides practical managerial recommendations and suggestions for future research.